Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tobacco company Star Scientific says its board of directors has approved the reorganization of the company's structure in a bid to pursue drug development for neurological diseases.
Subscribe to our email newsletter
The company intends to develop pharmaceutical products that use a botanical tobacco component for the treatment of smokeless tobacco dependence, as well as products that would utilize certain monoamine oxidase (MAO) agents in tobacco to treat a range of neurological conditions, including Alzheimer’s disease, Parkinson’s disease, schizophrenia and depression.
Star Scientific’s recently incorporated subsidiary in Delaware will be the vehicle for the company’s pursuit of a range of tobacco-based pharmaceutical products.
A search for a clinical/medical director who would oversee future clinical trials and the development of tobacco-related pharmaceutical products is currently underway.